Yixintang deploys convertible bond funds into structured deposits for cash management

Yixintang Pharmaceutical Group announced on November 17, 2025, that it is implementing cash management strategies with a portion of its idle funds. This follows the approval at the 2024 annual shareholders' meeting on May 21, 2025, to utilize up to RMB 325 million from its 2018 convertible bond offering for cash management, including fixed-income or principal-protected floating-rate products.

As part of this initiative, a subsidiary recently entered into a structured deposit agreement with Shanghai Pudong Development Bank's Kunming branch. Hongxiang Chinese Medicine Co., Ltd. purchased a "Lidoduo Company Stable 25JG4149 (6-month early bird C) RMB Public Structured Deposit" product with a principal-protected floating-rate structure. The investment amounts to RMB 3,500,000, with a start date of November 17, 2025, and an end date of May 18, 2026.

The product offers a guaranteed minimum yield of 0.95% and a floating yield that could range from 0% to 1.10% annually. This move is aimed at enhancing the efficiency of raised funds and improving overall company performance and shareholder returns.